ErbB- and MUC1-targetted CAR-T cell immunotherapy of oral squamous cell carcinoma

被引:0
|
作者
Summers, Saffron E. [1 ,2 ]
Salih, Vehid [2 ]
Foey, Andrew D. [1 ]
机构
[1] Univ Plymouth, Sch Biomed Sci, Fac Hlth, Plymouth, Devon, England
[2] Univ Plymouth, Sch Dent, Fac Hlth, Plymouth, Devon, England
来源
FRONTIERS IN DENTAL MEDICINE | 2023年 / 4卷
关键词
CAR-Ts; PD-L1; TAMs; ErbB; MUC1; OSCC; CANCER; HEAD; RECEPTORS;
D O I
10.3389/fdmed.2023.1116402
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
Chimeric antigen receptor T (CAR-T) cell therapy has shown great success in treating B cell malignancies however, there are many challenges which limit their therapeutic efficacy in solid tumours. Immunotherapy of head and neck squamous cell carcinoma (HNSCC), and in particular, oral squamous cell carcinoma (OSCC), presents a unique set of challenges including lack of consistently expressed tumour associated antigens (TAAs) and the immunosuppressive tumour microenvironment (TME). Currently, there are few clinical trials investigating the use of CAR-T cells in HNSCC/OSCC however results from trials investigating similar solid tumours, such as breast cancer, can be adopted to help evaluate the use of CAR-T in this cancer. In this review, the process of CAR-T cell engineering, and different generations of these cells will be summarised, highlighting their potential use in treating HNSCC through targeting ErbB and MUC1; TAAs highly expressed by this solid tumour. Potential strategies including combination therapy, utilising both TAA-targeting CAR-Ts and immune checkpoint inhibitors, such as PD-L1, has been discussed, in an attempt to develop synergistic anti-tumour responses. In addition to this, the use of dual-targeting CAR-T cells, synthetic NOTCH (synNOTCH) receptors and alternative non-tumour targets of the TME have been reviewed. Such combination therapies have been shown to help limit solid tumour progression and enhance both the safety and efficacy of CAR-T cell immunotherapy, which may be adopted for the treatment and management of OSCC.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] MUC1 and MUC4: Probable correlation with erbB receptors in oral squamous cell carcinoma
    Rios, A. D.
    Jimenez, M. D.
    Jacinto, L. F.
    Leyva, E. R.
    Hernandez, J. C.
    Cardiel, M.
    ORAL ONCOLOGY, 2009, : 209 - 209
  • [2] MUC1 as a target for CAR-T therapy in head and neck squamous cell carinoma
    Mei, Zi
    Zhang, Kai
    Lam, Alfred King-Yin
    Huang, Junwen
    Qiu, Feng
    Qiao, Bin
    Zhang, Yi
    CANCER MEDICINE, 2020, 9 (02): : 640 - 652
  • [3] Intratumoral pan-ErbB targeted CAR-T for head and neck squamous cell carcinoma: interim analysis of the T4 immunotherapy study
    Papa, Sophie
    Adami, Antonella
    Metoudi, Michael
    Beatson, Richard
    George, Molly Sarah
    Achkova, Daniela
    Williams, Evangelia
    Arif, Sefina
    Reid, Fiona
    Elstad, Maria
    Beckley-Hoelscher, Nicholas
    Douri, Abdel
    Delord, Marc
    Lyne, Mike
    Shivapatham, Dharshene
    Fisher, Christopher
    Hope, Andrew
    Gooljar, Sakina
    Mitra, Arindam
    Gomm, Linda
    Morton, Cienne
    Henley-Smith, Rhonda
    Thavaraj, Selvam
    Santambrogio, Alice
    Andoniadou, Cynthia
    Allen, Sarah
    Gibson, Victoria
    Cook, Gary J. R.
    Parente-Pereira, Ana C.
    Davies, David M.
    Farzaneh, Farzin
    Schurich, Anna
    Guerrero-Urbano, Teresa
    Jeannon, Jean-Pierre
    Spicer, James
    Maher, John
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (06)
  • [4] Advances in CAR-T Cell Therapy in Head and Neck Squamous Cell Carcinoma
    Wang, Han-Qi
    Fu, Ruxing
    Man, Qi-Wen
    Yang, Guang
    Liu, Bing
    Bu, Lin-Lin
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (06)
  • [5] Advances and challenges in CAR-T cell therapy for head and neck squamous cell carcinoma
    Sahand Saeidpour Masouleh
    Kamyar Nasiri
    Ava Ostovar Ravari
    Mona Saligheh Rad
    Kiarash kiani
    Ali Sharifi Sultani
    Seyedeh Tabasom Nejati
    Mohsen Nabi Afjadi
    Biomarker Research, 13 (1)
  • [6] Graduate training in T cell immunotherapy and CAR-T cell therapy
    Sterner, Rosalie
    Hedin, Karen E.
    Hayden, Richard E.
    Nowakowski, Grzegorz S.
    Wyles, Saranya P.
    Greenberg-Worisek, Alexandra J.
    Terzic, Andre
    Kenderian, Saad S.
    JOURNAL OF IMMUNOLOGY, 2020, 204 (01):
  • [7] MUC1 as a Target for CAR-T Therapy in Head and Neck Squamous Cell Carcinoma (vol 9, pg 640, 2020)
    Mei, Zi
    Zhang, Kai
    Lam, Alfred King-Yin
    Huang, Junwen
    Qiu, Feng
    Qiao, Bin
    Zhang, Yi
    CANCER MEDICINE, 2025, 14 (01):
  • [8] Effect of the antibody immunotherapy by the anti-MUC1 monoclonal antibody to the oral squamous cell carcinoma
    Imai, Masaki
    MOLECULAR IMMUNOLOGY, 2008, 45 (16) : 4179 - 4179
  • [9] T Cell Exhaustion and CAR-T Immunotherapy in Hematological Malignancies
    Tang, Lu
    Zhang, Yinqiang
    Hu, Yu
    Mei, Heng
    BIOMED RESEARCH INTERNATIONAL, 2021, 2021
  • [10] Targeting MUC1 with fisetin in oral squamous cell carcinoma
    Wang, Qian
    Zhang, Hongyan
    Xiang, Shuzhen
    Zhang, Lan
    Fan, Jiajia
    Xu, Zengyan
    Zhao, Fengfei
    Liu, Minda
    Li, Yanshu
    Dai, Wei
    GENES & DISEASES, 2025, 12 (03)